Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 92159305 | Other Identifier | The National Natural Science Foundation of China | |
| 82030047 | Other Identifier | The National Natural Science Foundation of China | |
| 82325027 | Other Identifier | The National Natural Science Foundation of China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Chinese Academy of Sciences | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
An artificial intelligence (AI) model to predict MVI of HCC using contrast-enhanced ultrasound was constructed. This model also has biological explainability. The investigators named it as MAPUSE (MVI AI prediction via contrast-enhanced ultrasound with explainability).
The goal of MAPUSE study is to prospectively test the performance of MAPUSE model on MVI prediction and its biological correlation in different geographical areas of China.
The presence of microvascular invasion (MVI) in hepatocellular carcinoma (HCC) is a critical prognostic indicator, but its preoperative diagnosis remains challenging. Contrast-enhanced ultrasound (CEUS), with its dynamic microvascular imaging capability, holds promise in prediction of MVI.
The investigators constructed an artificial intelligence (AI) model to predict MVI using contrast-enhanced ultrasound. This model also has biological explainability. We named it as MAPUSE (MVI AI prediction via contrast-enhanced ultrasound with explainability).
The goal of MAPUSE study is to prospectively test the performance of MAPUSE model on MVI prediction and its biological correlation in different geographical areas of China.
The performance of MAPUSE is to be tested in two prospective testing cohorts from two centers in southern and northern China. Before surgery, patient CEUS videos will be collected and analysed by MAPUSE model to generate an MVI risk score. According to the postoperative pathological diagnosis of MVI (golden criterion), the result of MAPUSE will be evaluated. Parameters include area under curve (AUC), accuracy (ACC), sensitivity, specificity and F1-score.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chinese PLA General Hospital Cohort | Patients from Chinese PLA General Hospital (northern China) after surgical treatment |
| |
| the First Affiliated Hospital of Sun Yat-sen University Cohort | Patients from the First Affiliated Hospital of Sun Yat-sen University (southern China) after surgical treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| the MAPUSE model | Diagnostic Test | Using the MAPUSE model to predict MVI status before surgical resection for HCC patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| area under operating characteristic curves (AUC) | the area under operating characteristic curves (AUC) to evaluate the performance of MAPUSE model in predicting MVI in HCC patients | From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively) |
| Measure | Description | Time Frame |
|---|---|---|
| ACC (accuracy) | The ratio of the number of samples correctly predicted by the model to the total number of samples | From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively) |
| Specificity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients who underwent surgical treatment for HCC
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chuan Pang | Chinese PLA General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| the First Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong | 510080 | China | ||
| Chinese PLA General Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
Proportion of all patients without MVI who are predicted negative by MAPUSE
| From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively) |
| Sensitivity | The proportion of patients with MVI that MAPUSE correctly identifies | From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively) |
| Beijing |
| 100853 |
| China |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |